Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 1.00 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | QDPR | P09417 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29559035 | 1.00 | HTR2C (1.00) | HTR2CSLC18A3SIGMAR1QDPRHTR6 | |
| Hydrochloric Acid SCHEMBL2802413 | 0.98 | HTR2C (1.00) | HTR2CSLC18A3SIGMAR1QDPRHTR6 | |
| SCHEMBL12058643 | 0.89 | HTR2C (0.80) | HTR2C | |
| Hydrochloric Acid SCHEMBL9311565 | 0.87 | HTR2C (0.81) | HTR2C | |
| SCHEMBL1515269 | 0.86 | HTR2C (0.74) | HTR2CMEN1KMT2A | |
| Toluene SCHEMBL27818685 | 0.82 | SLC18A3 (0.80) | HTR2CSLC18A3SIGMAR1HTR6KMT2A | |
| SCHEMBL2538410 | 0.82 | HTR2C (0.69) | HTR2CMEN1KMT2A | |
| SCHEMBL3069922 | 0.82 | HTR2C (0.69) | HTR2CMEN1KMT2A | |
| SCHEMBL2145468 | 0.80 | HTR2C (0.67) | HTR2C | |
| SCHEMBL3062414 | 0.80 | HTR2C (0.67) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731223-A1 | MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY | Universitat De Barcelona (ES) | 2026-04-29 | — | — | EP | disclosed |
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| CN-115362151-B | Arylpiperidines as monoacylglycerol lipase modulators | 詹森药业有限公司 | 2025-02-11 | — | — | CN | disclosed |
| WO-2024261340-A1 | MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY | UNIVERSITAT DE BARCELONA (ES) | 2024-12-26 | — | — | WO | disclosed |
| CN-118834313-A | Zwitterionic polymer, ion exchange membrane, and preparation methods and applications thereof | 佛山绿动氢能科技有限公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-117720721-B | Anion exchange polymer, ion exchange membrane, and preparation methods and application thereof | 国家电投集团氢能科技发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20240092781-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-21 | — | — | US | disclosed |
| CN-117720721-A | Anion exchange polymer, ion exchange membrane, and preparation methods and application thereof | 国家电投集团氢能科技发展有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-117487047-A | Phosphonic acid functionalized polymer, multifunctional styrene polymer and application thereof | 国家电投集团氢能科技发展有限公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20020193602-A1 | Novel opiate compounds, methods of making and methods of use | RESEARCH TRIANGLE INSTITUTE (US) | 2002-12-19 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
| EP-0126480-B1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES, METHOD FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1988-01-20 | — | — | EP | disclosed |
| US-4559403-A | FOR TREATMENT OF CEREBRAL AND CARDIAC ISCHEMIAS | HOFFMANN-LA ROCHE INC. (US) | 1985-12-17 | — | — | US | disclosed |
| US-4544657-A | ANTISCHEMIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1985-10-01 | — | — | US | disclosed |
| EP-0126480-A1 | Substituted isoquinoline derivatives, method for their preparation, and pharmaceutical compositions containing these compounds | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-11-28 | — | — | EP | disclosed |
| US-4077958-A | ANTIDEPRESSANTS | E. R. SQUIBB & SONS, INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4007191-A | ANTIDEPRESSANT | E. R. SQUIBB & SONS, INC. (US) | 1977-02-08 | — | — | US | disclosed |
| US-3935227-A | ANTIDEPRESSANTS, ANTIANXIETY, ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092781-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | HTR2C 64/4885SLC18A3 593/4885SIGMAR1 147/4885 |
| US-20020193602-A1 | Novel opiate compounds, methods of making and methods of use | OPRK1, OPRM1, OPRL1 | HTR2C 94/4885SLC18A3 26/4885SIGMAR1 6/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | HTR2C 235/4885SLC18A3 919/4885SIGMAR1 2679/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | HTR2C 9/4885SLC18A3 162/4885SIGMAR1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.